Patients & Caregivers
Dosing of Patients in ARQ 087 Trial Underway
ArQule announced today that registrational trial of derazantinib (ARQ 087) in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma, has initiated the dosing of patients.
PHA Keeps Heart in the Right Place with Awareness Campaign
The Pulmonary Hypertension Association is observing today, November 21, as Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Awareness Day.
Hemophilic Artropathy Treatment Granted Orphan Drug Designation
Tremeau Pharmaceuticals, Inc. was granted orphan drug designation this morning for TRM-201 (rofecoxib), intended for the treatment of hemophilic arthropathy.
Richard Bryce of Puma Biotechnology Talks Neratinib in Fibrolamellar
Richard Bryce of Puma Biotechnology discusses his company’s interest in neratinib and working with fibrolamellar cancer.
Approval of Stutent Expanded to Reduce Carcinoma Recurrence
Stutent (sunitinib malate), which was developed by Pfizer and originally approved by the FDA in 2006 for gastrointestinal stromal tumors, received an approval expansion today.
FDA Gives Go-Ahead to Obinutuzumab for Follicular Lymphoma Treatment
On the same day that Genentech received U.S. FDA approval for emicizumab, the regulatory agency has also given the green light to Gazyva to treat follicular lymphoma.
FDA Approves Hemlibra to Treat Bleeding in Hemophilia A Patients
The U.S. Food and Drug Administration (FDA) approved Genentech’s Hemlibra for patients with hemophilia A who have developed Factor VIII inhibiting antibodies.
Marketing Applications Accepted for FCS Treatment in US, Canada and Europe
This morning, Akcea announced that all its marketing applications for volanesorsen have been accepted for review in the United States, Europe and Canada.
John Gordan of UCSF Discusses His Work in Fibrolamellar Carcinoma
John Gordan of UCSF discusses his experience in fibrolamellar, and what he’s been seeing with his most recent research.
New Data Shows Positive Effects of BLU-285 in Gastrointestinal Tumors
New Phase 1 clinical data for BLU-285 supports previous data that demonstrated the drug as exhibiting strong clinical activity and an encouraging safety profile.
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
RARE DISEASE INFOGRAPHIC >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.